DCGI | Zee News

Advertisement

DCGI News

12 Feb 2023

Amazon, Flipkart & 18 E-Tailors Given Notices for Selling Drugs Sans Licence

The notice states that the sale or stock or exhibit or offer for sale or distribution of any drug requires a licence from the concerned state licensing authority and conditions of a licence are required to be complied with by the licence holders.

Gambia Children Deaths

15 Oct 2022

Gambia cough syrup deaths: Govt panel says info shared by WHO inadequate

Rutendo Kuwana from the WHO on October 13 had written to the DCGI seeking to know the progress with the investigation of the manufacturer of the four cough syrups -- the Sonipat-based Maiden Pharmaceuticals.

04 Jun 2022

CORBEVAX becomes first vaccine in India to get approval for COVID booster dose

CORBEVAX has become the first vaccine in India to get DCGI approval for COVID-19 booster dose. People who are 18 years & above & have already taken two doses of either COVISHIELD or COVAXIN can now receive a dose of CORBEVAX. The vaccine can be taken after 6 months of two doses of Covaxin or Covishield vaccines for restricted use in emergency situation.

26 Apr 2022

Vaccine Breaking : DCGI grants emergency approval to Covaxin and Corbevax for children below 12

In India, now even 5-year-old children can be given vaccinated against coronavirus. Corbevax vaccine of Biological E Company has been approved for those between 5 to 12 years of age while Covaxin will be given to children between 6 to 12 years of age. These vaccines are administered in two doses each of which is given at an interval of 28 to 40 days

09 Mar 2022

SII's ‘Covovax’ gets emergency use nod for children aged above 12 years

"Novavax in global trials has demonstrated more than 90 per cent efficacy. Serum Institute of India`s brand Covovax has completed bridging studies in India and has been granted Emergency Use Authorisation by DCGI for adults and for children above the age of 12. Younger age groups will follow shortly," SII CEO Adar Poonawala said in a tweet.

05 Jan 2022

Bharat Biotech gets approval to test nasal COVID-19 shot as booster

India's drug regulator DCGI on Wednesday granted approval to Bharat Biotech for conducting late-stage trials of its nasal COVID-19 vaccine to be used as a booster shot, according to news agency ANI.

29 Dec 2021

Corbevax, Covovax, Molnupiravir: All about India's 3 new COVID19 vaccines

Six COVID-19 vaccines - Serum Institute's Covishield, Bharat Biotech's Covaxin, Zydus Cadila's ZyCoV-D, Russia's Sputnik V and the US-made Moderna and Johnson and Johnson - had already received EUA from the Indian drug regulator earlier.

Serum Institute of India

01 Dec 2021

Third jab soon? Serum Institute asks DCGI to allow Covishield as booster dose

SII cited adequate stock of the vaccine in the country and a demand for a booster.

01 Dec 2021

Breaking News: Serum Institute seeks permission from DCGI for Booster Dose

Serum Institute sought permission from DCGI for Booster Dose. Serum Institute's vaccine is Covishield.

12 Oct 2021

COVID-19: Covaxin recommended for 2 to 18-year-olds in India

The development comes amid India closing in on 100 crore vaccination coverage.

08 Sep 2021

Centre forms panel to frame law to regulate drugs, cosmetics, medical devices

Centre has formed a panel to chalk out new law for regulating drugs, cosmetics and medical devices The panel will be headed by the DCGI The panel will submit draft report by November 30

13 Jul 2021

Serum Institute to produce Sputnik V vaccine from September

SII to begin Sputnik vaccine production in September Parties intend to produce 300 mn vaccine doses in India per year

08 Jul 2021

DCGI gives nod for Sanofi-GSK's phase 3 trial of COVID vaccine in India

DCGI has given nod for Sanofi-GSK's phase 3 trial of COVID vaccine in India The French pharma company Sanofi and its British peer GSK aim to produce up to one billion doses in 2021

04 Jun 2021

Serum Institute gets DCGI nod to manufacture Sputnik V vaccine in India

SII gets DCGI nod to manufacture Sputnik V It has collaborated with Moscow's Gamaleya Research Institute of Epidemiology and Microbiology It will manufacture vaccines at its Hadapsar facility

Serum Institute of India

03 Jun 2021

SII applies to DCGI to manufacture COVID vaccine Sputnik V, seeks indemnity

Serum Institute of India has applied to DCGI to manufacture COVID vaccine Sputnik V The Pune-based firm has also sough indemnity

28 May 2021

India to import vaccines to speed up vaccination of entire population

Health Care Workers vaccination started on January 16, 2021 The Phase-III of COVID-19 vaccination has begun from 1st May 2021 The Russian Sputnik V is the third vaccine to get approval from DCGI for restricted use in an emergency situation

24 May 2021

Amphotericin B: Why is this drug used in Black Fungus treatment, Zee explains

Amphotericin B is a rare drug used in the Black Fungus treatment It is believed that nearly 7,000 people have been infected in India with the black fungus Over 200 have lost their lives

10 May 2021

DRDO's easily producible 2-DG drug helps in faster recovery of COVID!

In efficacy trends, the patients treated with 2-DG showed faster symptomatic cure than Standard of Care (SoC) on various endpoints Being a generic molecule (2-DG) and analogue of glucose, it can be easily produced and made available in plenty in the country

09 May 2021

COVID-19 Vaccine: DCGI approves anti-COVID drug developed by DRDO

The Institute of Nuclear Medicine and Allied Sciences in collaboration with Dr Reddy’s Laboratories, Hyderabad, developed an anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG).

03 Jan 2021

Covaxin and Covishield approved, know which is more effective in both vaccines and how much is the price?

DCGI on Sunday approved the emergency use of Covishield of Serum Institute and Bharat Biotech's Covaxin. Of which Covishield will be the first to start vaccination, Covaxin will remain as an option. The general public will get the vaccine by April - May.

Loading...

NEWS ON ONE CLICK